Shares of Ipca Laboratories declined by 2.65% to Rs 1,402.80 in Monday's session, emerging among the top losers on the Nifty Midcap 150 index. At 9:29 am, the stock was trading lower, reflecting the broad market sentiment.
Financial Snapshot:
The following tables summarize the consolidated financial performance of Ipca Laboratories.
Quarterly Results:
| Heading | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 2,092.63 Crore | Rs 2,354.90 Crore | Rs 2,245.37 Crore | Rs 2,246.69 Crore | Rs 2,308.85 Crore |
| Net Profit | Rs 198.98 Crore | Rs 245.44 Crore | Rs 277.33 Crore | Rs 65.78 Crore | Rs 234.42 Crore |
| EPS | 7.58 | 9.05 | 9.78 | 2.67 | 9.19 |
Annual Results:
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 5,419.99 Crore | Rs 5,829.79 Crore | Rs 6,244.32 Crore | Rs 7,705.04 Crore | Rs 8,939.59 Crore |
| Net Profit | Rs 1,148.84 Crore | Rs 910.95 Crore | Rs 491.93 Crore | Rs 529.21 Crore | Rs 787.53 Crore |
| EPS | 45.01 | 34.85 | 18.58 | 25.82 | 35.14 |
| BVPS | 371.79 | 219.51 | 233.16 | 304.57 | 273.88 |
| ROE | 24.24 | 16.09 | 8.06 | 8.64 | 10.61 |
| Debt to Equity | 0.05 | 0.14 | 0.25 | 0.22 | 0.19 |
Annual Income Statement:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Sales | 8,939 | 7,705 | 6,244 | 5,829 | 5,419 |
| Other Income | 92 | 124 | 125 | 66 | 62 |
| Total Income | 9,032 | 7,829 | 6,369 | 5,896 | 5,482 |
| Total Expenditure | 7,816 | 6,848 | 5,579 | 4,752 | 4,084 |
| EBIT | 1,216 | 980 | 790 | 1,143 | 1,398 |
| Interest | 84 | 138 | 45 | 7 | 9 |
| Tax | 343 | 313 | 253 | 224 | 240 |
| Net Profit | 787 | 529 | 491 | 910 | 1,148 |
Quarterly Income Statement:
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | |
|---|---|---|---|---|---|
| Sales | 2,308 | 2,246 | 2,245 | 2,354 | 2,092 |
| Other Income | 32 | 25 | 20 | 26 | 20 |
| Total Income | 2,341 | 2,272 | 2,265 | 2,381 | 2,113 |
| Total Expenditure | 1,992 | 2,123 | 1,880 | 2,013 | 1,798 |
| EBIT | 349 | 149 | 384 | 367 | 314 |
| Interest | 18 | 21 | 16 | 22 | 24 |
| Tax | 96 | 62 | 90 | 99 | 91 |
| Net Profit | 234 | 65 | 277 | 245 | 198 |
Cash Flow:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Operating Activities | 1,321 | 944 | 805 | 856 | 1,090 |
| Investing Activities | -869 | -1,291 | -725 | -855 | -520 |
| Financing Activities | -282 | -552 | 507 | 426 | -305 |
| Others | 0 | 76 | 0 | 4 | 0 |
| Net Cash Flow | 168 | -823 | 588 | 431 | 263 |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Share Capital | 25 | 25 | 25 | 25 | 25 |
| Reserves & Surplus | 6,923 | 6,306 | 5,816 | 5,466 | 4,676 |
| Current Liabilities | 2,386 | 2,355 | 1,805 | 1,465 | 1,160 |
| Other Liabilities | 2,425 | 2,413 | 978 | 681 | 206 |
| Total Liabilities | 11,760 | 11,101 | 8,626 | 7,638 | 6,068 |
| Fixed Assets | 4,798 | 4,805 | 2,853 | 2,669 | 2,260 |
| Current Assets | 6,268 | 5,538 | 5,189 | 4,457 | 3,436 |
| Other Assets | 694 | 756 | 583 | 511 | 370 |
| Total Assets | 11,760 | 11,101 | 8,626 | 7,638 | 6,068 |
| Contingent Liabilities | 613 | 303 | 2,125 | 274 | 369 |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 35.14 | 25.82 | 18.58 | 34.85 | 45.01 |
| Diluted Eps (Rs.) | 29.08 | 21.57 | 18.58 | 34.85 | 45.01 |
| Book Value [Excl. Reval Reserve]/Share (Rs.) | 273.88 | 304.57 | 233.16 | 219.51 | 371.79 |
| Dividend/Share (Rs.) | 4.00 | 4.00 | 4.00 | 4.00 | 8.00 |
| Face Value | 1 | 1 | 1 | 1 | 2 |
| Gross Profit Margin (%) | 20.34 | 18.76 | 16.85 | 23.59 | 29.65 |
| Operating Margin (%) | 15.89 | 14.12 | 12.66 | 19.61 | 25.79 |
| Net Profit Margin (%) | 8.80 | 6.86 | 7.87 | 15.62 | 21.19 |
| Return on Networth / Equity (%) | 10.61 | 8.64 | 8.06 | 16.09 | 24.24 |
| ROCE (%) | 15.15 | 12.44 | 11.59 | 18.52 | 28.48 |
| Return On Assets (%) | 6.27 | 4.93 | 5.46 | 11.57 | 18.78 |
| Current Ratio (X) | 2.63 | 2.35 | 2.87 | 3.04 | 2.96 |
| Quick Ratio (X) | 1.55 | 1.30 | 1.91 | 1.77 | 1.59 |
| Debt to Equity (x) | 0.19 | 0.22 | 0.25 | 0.14 | 0.05 |
| Interest Coverage Ratios (X) | 21.42 | 10.46 | 23.11 | 178.91 | 177.79 |
| Asset Turnover Ratio (%) | 0.78 | 0.78 | 0.77 | 0.80 | 0.91 |
| Inventory Turnover Ratio (X) | 3.55 | 1.05 | 0.95 | 0.96 | 1.10 |
| 3 Yr CAGR Sales (%) | 23.83 | 19.23 | 15.90 | 24.30 | 28.99 |
| 3 Yr CAGR Net Profit (%) | -7.02 | -32.13 | -10.30 | 43.23 | 117.14 |
| P/E (x) | 42.74 | 47.92 | 43.61 | 30.58 | 21.15 |
| P/B (x) | 5.48 | 4.96 | 3.52 | 4.90 | 5.13 |
| EV/EBITDA (x) | 22.26 | 23.45 | 19.23 | 19.73 | 14.96 |
| P/S (x) | 4.26 | 4.08 | 3.29 | 4.62 | 4.45 |
Ipca Laboratories has announced several corporate actions, including dividend payouts. The company announced a final dividend of Rs 2.00 per share (200%) on May 29, 2025, with an effective date of August 5, 2025. Other corporate actions include relodgement of transfer requests for physical shares and newspaper publications.
Moneycontrol analysis on September 19, 2025, indicated a very bullish sentiment for the stock.
With the stock's last traded price at Rs 1,402.80, Ipca Laboratories reflects a decline amid broader market activity.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
